A phase 3 trial of semagacestat for treatment of Alzheimer's disease
- PMID: 23883379
- DOI: 10.1056/NEJMoa1210951
A phase 3 trial of semagacestat for treatment of Alzheimer's disease
Abstract
Background: Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer's disease.
Methods: We conducted a double-blind, placebo-controlled trial in which 1537 patients with probable Alzheimer's disease underwent randomization to receive 100 mg of semagacestat, 140 mg of semagacestat, or placebo daily. Changes in cognition from baseline to week 76 were assessed with the use of the cognitive subscale of the Alzheimer's Disease Assessment Scale for cognition (ADAS-cog), on which scores range from 0 to 70 and higher scores indicate greater cognitive impairment, and changes in functioning were assessed with the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale, on which scores range from 0 to 78 and higher scores indicate better functioning. A mixed-model repeated-measures analysis was used.
Results: The trial was terminated before completion on the basis of a recommendation by the data and safety monitoring board. At termination, there were 189 patients in the group receiving placebo, 153 patients in the group receiving 100 mg of semagacestat, and 121 patients in the group receiving 140 mg of semagacestat. The ADAS-cog scores worsened in all three groups (mean change, 6.4 points in the placebo group, 7.5 points in the group receiving 100 mg of the study drug, and 7.8 points in the group receiving 140 mg; P=0.15 and P=0.07, respectively, for the comparison with placebo). The ADCS-ADL scores also worsened in all groups (mean change at week 76, -9.0 points in the placebo group, -10.5 points in the 100-mg group, and -12.6 points in the 140-mg group; P=0.14 and P<0.001, respectively, for the comparison with placebo). Patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events (P<0.001 for all comparisons with placebo). Laboratory abnormalities included reduced levels of lymphocytes, T cells, immunoglobulins, albumin, total protein, and uric acid and elevated levels of eosinophils, monocytes, and cholesterol; the urine pH was also elevated.
Conclusions: As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT00594568.)
Comment in
-
Semagacestat for treatment of Alzheimer's disease.N Engl J Med. 2013 Oct 24;369(17):1661. doi: 10.1056/NEJMc1310845. N Engl J Med. 2013. PMID: 24152267 No abstract available.
-
Semagacestat for treatment of Alzheimer's disease.N Engl J Med. 2013 Oct 24;369(17):1660-1. doi: 10.1056/NEJMc1310845. N Engl J Med. 2013. PMID: 24152268 No abstract available.
-
Semagacestat for treatment of Alzheimer's disease.N Engl J Med. 2013 Oct 24;369(17):1661. doi: 10.1056/NEJMc1310845. N Engl J Med. 2013. PMID: 24152269 No abstract available.
Similar articles
-
Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.N Engl J Med. 2018 May 3;378(18):1691-1703. doi: 10.1056/NEJMoa1706441. N Engl J Med. 2018. PMID: 29719179 Free PMC article. Clinical Trial.
-
Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease.J Alzheimers Dis. 2016 Aug 10;54(1):373-81. doi: 10.3233/JAD-151113. J Alzheimers Dis. 2016. PMID: 27567808
-
Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings.Curr Med Res Opin. 2014 Oct;30(10):2021-32. doi: 10.1185/03007995.2014.939167. Epub 2014 Jul 14. Curr Med Res Opin. 2014. PMID: 24983746 Clinical Trial.
-
Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.Expert Opin Drug Discov. 2012 Jan;7(1):19-37. doi: 10.1517/17460441.2012.645534. Epub 2011 Dec 14. Expert Opin Drug Discov. 2012. PMID: 22468891 Review.
-
Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.Expert Opin Pharmacother. 2009 Jul;10(10):1657-64. doi: 10.1517/14656560903044982. Expert Opin Pharmacother. 2009. PMID: 19527190 Review.
Cited by
-
Review on anti-alzheimer drug development: approaches, challenges and perspectives.RSC Adv. 2024 Apr 5;14(16):11057-11088. doi: 10.1039/d3ra08333k. eCollection 2024 Apr 3. RSC Adv. 2024. PMID: 38586442 Free PMC article. Review.
-
Towards a Unitary Hypothesis of Alzheimer's Disease Pathogenesis.J Alzheimers Dis. 2024;98(4):1243-1275. doi: 10.3233/JAD-231318. J Alzheimers Dis. 2024. PMID: 38578892 Free PMC article.
-
New precision medicine avenues to the prevention of Alzheimer's disease from insights into the structure and function of γ-secretases.EMBO J. 2024 Mar;43(6):887-903. doi: 10.1038/s44318-024-00057-w. Epub 2024 Feb 23. EMBO J. 2024. PMID: 38396302 Free PMC article. Review.
-
Presenilin: A Multi-Functional Molecule in the Pathogenesis of Alzheimer's Disease and Other Neurodegenerative Diseases.Int J Mol Sci. 2024 Feb 1;25(3):1757. doi: 10.3390/ijms25031757. Int J Mol Sci. 2024. PMID: 38339035 Free PMC article. Review.
-
Alzheimer's Disease: Models and Molecular Mechanisms Informing Disease and Treatments.Bioengineering (Basel). 2024 Jan 1;11(1):45. doi: 10.3390/bioengineering11010045. Bioengineering (Basel). 2024. PMID: 38247923 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials